Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, September 1998, p. 2197-2205, Vol. 42, No. 9
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Molecular Mode of Action of the Antifungal
-Amino Acid BAY 10-8888
Karl
Ziegelbauer,1,*
Peter
Babczinski,2 and
Wolfgang
Schönfeld1
Institut für Antiinfektiva Forschung,
Bayer AG, D-42096 Wuppertal,1 and
Institut für Metabolismusforschung und
Rückstandanalytik, Bayer AG, D-40789
Monheim,2 Germany
Received 9 February 1998/Returned for modification 4 June
1998/Accepted 17 June 1998
 |
ABSTRACT |
BAY 10-8888 is a cyclic
-amino acid that is related to
cispentacin and that has antifungal activity. Candida
albicans cells accumulated BAY 10-8888 intracellularly to a
concentration about 200 that in the medium when grown in media with a
variety of nitrogen sources. In complex growth medium, BAY 10-8888 transport activity was markedly reduced and was paralleled by a
decrease in its antifungal activity. Uptake of BAY 10-8888 was mediated
by an H+-coupled amino acid transporter with specificity
for branched-chain amino acids (isoleucine, leucine, and valine) and
showed a KT (Michaelis constant of the
transport reaction) of 0.95 mM and a Vmax of
18.9 nmol × min
1 × 107
cells
1. Similar to the transport of natural amino acids
in Saccharomyces cerevisiae, the transport of BAY 10-8888 into the cell was unidirectional. Efflux occurred by diffusion and was
not carrier mediated. Inside the cell BAY 10-8888 inhibited
specifically isoleucyl-tRNA synthetase, resulting in inhibition of
protein synthesis and cell growth. Intracellular isoleucine reversed
BAY 10-8888-induced growth inhibition. BAY 10-8888 was not incorporated
into proteins. BAY 10-8888 inhibited isoleucyl-tRNA synthetase
with the same concentration dependency as protein biosynthesis in
intact cells assuming 200-fold accumulation.
 |
INTRODUCTION |
In 1989, cispentacin
[(1R,2S)-2-aminocyclopentane-1-carboxylic acid;
Fig. 1], a cyclic
-amino acid
isolated from Bacillus cereus (12) and,
subsequently, from Streptomyces setonii (9), was
described to have potent anti-Candida activity both in vitro and in a mouse model of systemic candidiasis (9, 12, 17, 18). At about the same time, aminocyclohexene carboxylic acids were designed as pyridoxal phosphate suicide inhibitors (1). One of those compounds
[(1R,2S)-2-amino-3-cyclohexene-1-carboxylic acid; Fig. 1] showed activity against Candida albicans as
well, and therefore, a derivatization program aimed at identifying
cyclic
-amino acid derivatives with superior efficacy and good
tolerability was started (1a). BAY 10-8888 [(1R,2S)-2-amino-4-methylene-cyclopentane-1-carboxylic acid; Fig. 1] showed in vitro activity against several
Candida spp. (3a) and was chosen for further
development.

View larger version (8K):
[in this window]
[in a new window]
|
FIG. 1.
Structures of the antifungal -amino acids BAY 10-8888 [(1R,2S)-2-amino-4-methylenecyclopentane-1-carboxylic
acid], cispentacin
[(1R,2S)-2-aminocyclopentane-1-carboxylic
acid], and BAY y 9379 [(1R,2S)-2-amino-3-cyclohexene-1-carboxylic
acid].
|
|
Since fungi and humans are eukaryotes, selectivity is one of the main
challenges in the development of new antifungal agents. Knowledge of
the mode of action is crucial to distinguish toxic side effects which
depend on the mode of action and, therefore, which are expected for all
members of a certain class of compounds from those effects which are
compound specific and which can be overcome by chemical derivatization.
For the cyclic
-amino acid cispentacin, Capobianco and coworkers
(2) suggested that the mode of action in C. albicans is interference with self-regulatory mechanisms of amino
acid metabolism after accumulation via amino acid carriers. However, no
information about the exact molecular target was provided.
Here, we show that BAY 10-8888 has a dual mode of action. First, it is
actively accumulated by amino acid permeases. Second, inside the cell,
BAY 10-8888 is a low-affinity inhibitor of isoleucyl-tRNA synthetase.
Inhibition of isoleucyl-tRNA synthetase results in the disruption of
protein biosynthesis and cell growth.
 |
MATERIALS AND METHODS |
Radioactive compounds.
Tritiated water
([3H]H2O; 1 mCi/ml),
inulin-[14C]carboxylic acid (6.1 mCi/mmol),
L-[14C]lysine (319 mCi/mmol, 160 µM), and
L-[14C]isoleucine (313 mCi/mmol, 150 µM)
were purchased from Amersham Buchler, Braunschweig, Germany.
[14C]BAY 10-8888 (12 mCi/mmol) was provided by M. Radtke,
Institute for Pharmacokinetics, Bayer AG. The radiochemical purity was
>96%.
Materials.
Filter disks either were from Millipore,
Eschborn, Germany, or were manufactured by Whatman, Kent, United
Kingdom. tRNA from brewer's yeast, tRNA from calf liver, and ATP were
purchased from Boehringer, Mannheim, Germany. All other chemicals were
obtained from Sigma, Deisenhofen, Germany. Nonlabelled BAY 10-8888 was prepared as described previously (1a) and was provided by J. Mittendorf, Institute for Chemistry. Fluconazole was synthesized at
Bayer AG.
Organisms.
C. albicans BSMY 212 (ATCC 200498) was
maintained by bimonthly transfer on Nervina agar (0.5% [vol/vol]
glycerol, 0.5% Bacto Peptone, 0.5% sodium chloride, 4% malt extract,
2% Bacto Agar [pH 7.0]). Saccharomyces cerevisiae ATCC
46790 (a/
trp1/trp1 ura3/ura3
[rho+] [cir+]) was grown in
minimal dextrose medium combined with supplement mixture (Bio 101, Inc., La Jolla, Calif.).
Overnight cultures in YPG medium (1.5% glucose, 1.0% peptone, 0.4%
yeast extract, 0.05% K2HPO4, 0.05%
MgSO4 · 7 H2O [pH 7.0]) were diluted
1:10 in fresh medium as indicated below and were incubated for about
4 h at 37°C to obtain logarithmic-phase culture cells. The
following media were used: YNG medium (0.67% Bacto Yeast Nitrogen Base
[Difco], 1.0% glucose [pH 7.0]), YNGW medium (0.67% Bacto Yeast
Nitrogen Base without amino acids [Difco], 1.0% glucose [pH 7.0]),
and YNGWA medium (0.67% Bacto Yeast Nitrogen Base without amino acids
and ammonium sulfate [Difco], 1.0% glucose [pH 7.0]).
Estimation of intracellular water space in C. albicans.
Logarithmic-phase C. albicans cells grown in
YNG or YPG medium at 37°C were harvested by centrifugation (at
1,850 × g for 10 min), washed once in ice-cold water,
and resuspended in phosphate-buffered saline (PBS) at a final density
of 109 cells/ml. A total of 100 µl of the cell suspension
was mixed with 100 µl of a mixture of 10 µCi of
inulin-[14C]carboxylic acid per ml and 10 µCi of
[3H]H2O per ml in PBS. After incubation for
60 s the cells were pelleted by centrifugation (at 15,850 × g for 15 s). The supernatant was removed carefully, and
the pellet was resuspended in 100 µl of 1% sodium dodecyl sulfate
(SDS). For each sample 40 µl of the pellet suspension and supernatant
was placed in duplicate into scintillation vials, and then 5 ml of
scintillation fluid (Quickszint 401; Zinsser Analytic, Frankfurt,
Germany) was added and the radioactivity was determined in a
three-channel liquid scintillation counter (Beckmann LS 3801; Beckman
Instruments, Munich, Germany). Channel settings were 0 to 400 for the
detection of 3H counts and 400 to 670 for the detection of
14C counts. Activity was corrected for quenching with
internal programs for quench compensation. The intracellular water
space was calculated from the ratios of the 3H
disintegrations per minute and the 14C disintegrations per
minute in the supernatant and pellet as described previously
(21). The data were evaluated under the assumptions
described previously (3).
Transport measurements.
For transport measurements
logarithmic-phase C. albicans cells grown in different media
were pelleted by centrifugation and washed once with sterile PBS. The
cell density was adjusted to 1.1 × 108/ml in
transport medium. In the standard assay 180 µl of cells (2 × 107 cells) was equilibrated to 37°C for 3 min. Prior to
the start of the reaction 10 µl of either PBS or a
20-fold-concentrated effector (inhibitor or competitor) solution was
added and the mixture was incubated at 37°C for various periods.
Uptake was started by adding 10 µl of 20-fold-concentrated
[14C]BAY 10-8888 (radioactivity concentration range, 0.12 to 5 µCi/ml). After incubation at 37°C for various periods, uptake
was stopped by the addition of 8 ml of ice-cold water. Cells were
collected on cellulose mixed ester filter disks (pore size, 0.22 µm;
GSTF; Millipore) and washed twice with 4 ml of ice-cold water.
Air-dried filters were placed into scintillation vials, and after the
addition of 5 ml of scintillation fluid the radioactivity was
determined. To determine the [14C]BAY 10-8888 concentration in the supernatants, the cells were pelleted in a
microcentrifuge (at 15,850 × g for 30 s) and 20 µl of the supernatant was processed as described above. For efflux measurements C. albicans cells were preloaded with
[14C]BAY 10-8888 for 30 min at 37°C. Thereafter, the
cells were pelleted by centrifugation (at 15,850 × g
for 60 s) and the supernatant was removed. The pellet was washed
once with 1.3 ml of ice-cold water, and the supernatant was removed
entirely. The cells were resuspended in ice-cold efflux medium, and an
aliquot was removed to determine the initial intracellular
[14C]BAY 10-8888 concentration. After the addition of
effector solution or PBS the cells were incubated at 37°C. At various
time points aliquots were removed and processed as described above.
Susceptibility testing and growth inhibition.
C.
albicans cells grown overnight in YPG medium at 28°C were
diluted 1:50 in YNG medium (or some other medium, as indicated) and
were incubated for 4 h at 28°C. An inoculum of 103
cells/ml was prepared, and 200 µl of the cell suspension was added to
a microtiter plate containing serial dilutions of the test compound in
50 µl of PBS. Control incubations without test compound were
included. The microtiter plate was incubated for 24 h at 37°C.
Endpoint reading was performed by determination of the optical density
at 540 nm. The 50% inhibitory concentration (IC50) was
defined as the compound concentration reducing growth to 50% of the
control value. IC90 was defined as the lowest compound concentration preventing visible growth. Susceptibility testing of
S. cerevisiae was performed as described above with YNG
medium supplemented with 75 µg of uridine per ml or minimal dextrose medium lacking tryptophan (Bio 101, Inc.). Endpoint reading was performed after 48 h of incubation at 37°C as described above.
To determine the intracellular BAY 10-8888 concentrations that inhibit
growth,
C. albicans cells grown overnight in YNG medium
at
37°C were inoculated at a cell density of 2 × 10
6/ml in YNG medium or YNG medium containing 1 mM
L-isoleucine and
were incubated with shaking at 37°C.
After 2 h, [
14C]BAY 10-8888 was added to a final
concentration of 50 µM. The
final concentration of radioactivity was
0.05 µCi/ml. At different
time points, samples were processed as
described above and the
intracellular BAY 10-8888 concentration was
determined. The numbers
of CFU were determined by plating an aliquot on
Nervina agar at
various time points.
Protein and nucleic acid labelling.
Logarithmic-phase
C. albicans cells grown in YNG or YPG medium at 37°C were
harvested by centrifugation (at 1,850 × g for 10 min),
washed twice in ice-cold PBS, and resuspended in YNG medium at a
density of 2.2 × 107 cells/ml. A total of 450 µl of
this cell suspension was added to 50 µl of a 10-fold-concentrated
inhibitor solution, and the mixture was incubated at 37°C for various
periods. Cells were pulsed by the addition of 50 µl of
L-[14C]lysine (final concentration, 20 µM,
0.15 µCi/ml) or [14C]adenine (final concentration, 45 µM, 1 µCi/ml). The L-[14C]lysine
incorporation was stopped by adding 50 µl of a 10% SDS solution, 50 µl of bovine serum albumin solution (1 mg/ml in PBS), and 650 µl of
20% trichloroacetic acid (TCA) containing 2 mg of L-lysine
per ml. The mixture was incubated for 15 min at 80°C, cooled to room
temperature, and kept on ice for a further 30 min. [14C]adenine incorporation was stopped by adding 50 µl
of a 10% SDS solution and 600 µl of 20% TCA containing 0.5 mg of
adenine per ml. The mixture was incubated for 15 min at 90°C and
cooled to room temperature. The samples were trapped on glass fiber
filters (GF/C; Whatman). The filters were washed twice with 5 ml of
ice-cold 10% TCA, 1 mg of L-lysine per ml, or 5 ml of 10%
TCA-1 mg of adenine per ml and twice with 5 ml of ethanol. Thereafter,
the filters were air dried and the radioactivity was determined.
Cell lysis and S100 preparation.
C. albicans cells
grown overnight in YPG medium at 28°C were diluted 1:20 in YNG medium
or 1:200 in YPG medium and were incubated overnight at 37°C with
shaking. The cells were chilled on ice, harvested by centrifugation (at
1,850 × g for 10 min), and washed once with 0.4 volume
of ice-cold lysis buffer (100 mM Tris-Cl, 1 mM EDTA, 1 mM
dithiothreitol, 100 µg of phenylmethylsulfonyl fluoride per ml, 100 µg of
N
-p-tosyl-L-lysine
chloromethylketone per ml, 2 µg of aprotinin per ml, 1 mM
benzamidine, and 0.3 M KCl [pH 7.4]; freshly prepared). The washed
pellets were resuspended in 3 ml of ice-cold lysis buffer/g of pellet.
The Candida suspension was poured slowly into the same
volume of liquid nitrogen. After the addition of 2 volumes of
acid-washed glass beads (diameter, 425 to 600 µm; Sigma, Deisenhofen, Germany) the cells were broken by repeated cycles (about 15) of vigorous vortexing and cooling on ice (30 s of vortexing, 15 s of
cooling). Thereafter, the beads were removed by centrifugation and were
washed once with lysis buffer. The supernatants were pooled and
centrifuged at 100,000 × g for 60 min. The supernatant from the centrifugation at 100,000 × g (S100) was
quickly frozen in liquid nitrogen and was stored at
70°C.
Aminoacyl-tRNA synthetase activity.
The
L-isoleucyl- and L-lysyl-tRNA synthetase
activities in the S100 fraction were determined by a filtration method
(5, 14). Briefly, C. albicans aminoacyl-tRNA
synthetase activity was measured after the addition of the S100 extract
to a reaction mixture containing 0.1 M Tris-Cl (pH 7.65), 0.1 M KCl, 10 mM MgSO4, 0.5 mM EDTA, 2 mM ATP, 15 µg of tRNA from
brewer's yeast per ml, and 9.6 µM
L-[14C]isoleucine (3 µCi/ml) or 9 µM
L-[14C]lysine (3 µCi/ml). After incubation
for 1, 2, 3, and 4 min (alternatively, 2, 4, 6, and 8 min) at 37°C,
20 µl of the reaction mixture was removed and was spotted onto
Whatman 3MM filter disks which had been soaked with 50 µl of 10% TCA
and dried. The disks were washed once with ice-cold 10% TCA containing
1 mg of L-isoleucine per ml and 1 mg of
L-lysine per ml and were placed in ice-cold 10% TCA
containing 1 mg of L-isoleucine and L-lysine
per ml for at least 15 min. Thereafter, the disks were washed for at
least 10 min with ice-cold 5% TCA containing 1 mg of
L-isoleucine and L-lysine per ml and were
briefly rinsed with ethanol. The disks were dried under a heat lamp,
and the amount of trapped radioactivity was determined as described
above. Assays were performed in triplicate. Protein concentrations were
determined by the bicinchoninic acid method (Pierce Chemical Company,
Rockford, Ill.) after precipitation of an aliquot with 3 volumes
of methanol. The results were expressed as specific activities (units
per milligram of protein; 1 U is defined as the capacity to
aminoacylate 1 nmol of tRNA per min under standard assay conditions).
Overexpression of isoleucyl-tRNA synthetase in S. cerevisiae.
A 3.27-kb EcoRI-BamHI fragment
from pILS (14) coding for isoleucyl-tRNA synthetase was
blunt ended and cloned into the blunt-ended BamHI site of
the yeast expression vector pG-1 (22). The resulting construct (pAL664) encodes yeast isoleucyl-tRNA synthetase under the
control of the constitutive glyceraldehyde-3-phosphate dehydrogenase promoter (22). S. cerevisiae ATCC 46790 was
transformed with pG-1 or pAL664 by using a yeast spheroplast
transformation kit according to the manufacturer's instructions (Bio
101, Inc.). Transformants were selected and propagated on minimal
dextrose medium lacking tryptophan (Bio 101, Inc.) or YNG medium
supplemented with 75 µg of uridine per ml.
Data analysis.
Data obtained from saturation and inhibition
experiments were analyzed with the Prism program (GraphPad Software
Inc., San Diego, Calif.) for microcomputers.
 |
RESULTS |
The structure of BAY 10-8888 and initial observations by
Capobianco and coworkers (2) suggested that the antifungal
activity of BAY 10-8888 may result from interference with the amino
acid metabolism of C. albicans. Furthermore, the
sensitivity of C. albicans to BAY 10-8888 was dependent
on medium composition. The minimal inhibitory concentration
(IC90) was 4 µg/ml (28 µM) in YNG medium, a
minimal medium containing ammonium sulfate as the nitrogen source and
glucose as the carbon source, and >64 µg/ml (>448 µM) in YPG
medium, a complex medium containing yeast extract, peptone, and
glucose. Therefore, we tested the influence of naturally occurring
L-amino acids, their enantiomers, and related amino acids
on the inhibitory concentration for 50% growth inhibition (IC50) of BAY 10-8888 against C. albicans. The
amino acids which affected the IC50 of BAY 10-8888 are
shown in Table 1. Concomitant incubation with 1 mM D-isoleucine,
L-leucine, D-leucine,
D-methionine, L-valine, or
-alanine
increased the IC50 of BAY 10-8888 16-fold, while the
addition of 1 mM L-isoleucine resulted in a 125-fold increase. All other L- and D-amino acids tested
as well as D-norleucine, cis- and
trans-hydroxyproline, pyroglutamic acid,
L-ornithine, sarcosine, and citrulline did not affect the
IC50 (data not shown). We also tested the influence of the
corresponding
-keto acids of L-isoleucine
(DL-
-keto-
-methylvaleric acid), L-leucine
(
-ketoisocaproic acid), and L-valine
(
-ketoisovaleric acid) at 1 mM concentrations on the
IC50. The presence of 1 mM
-ketoisocaproic acid or 1 mM
-ketoisovaleric acid did not significantly influence the
IC50 of BAY 10-8888 (the differences were below a factor of
2), whereas 1 mM DL-
-keto-
-methylvaleric acid
increased the IC50 to 6.25 µg/ml. As shown in Table 1,
the amino acids that decreased the sensitivity to BAY 10-8888 at
least 10-fold belong to the class of branched-chain amino acids.
To test whether competition for uptake was responsible for the
decreased BAY 10-8888 sensitivity in the presence of
branched-chain amino acids, we characterized the
uptake of BAY 10-8888 in the presence of
-amino acids into C. albicans cells.
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Effects of branched-chain amino acids and their
respective -keto acids on BAY 10-8888 susceptibility of C. albicans BSMY 212a
|
|
Inhibition of BAY 10-8888 uptake by
-amino acids.
As shown
in Fig. 2A only the branched-chain amino
acids L-isoleucine, L-leucine, and
L-valine reduced uptake to 51, 57, and 55% of the control
value, respectively, when they were present at a 20-fold excess. This
suggested that BAY 10-8888 is accumulated by an amino acid carrier
specific for branched-chain amino acids. In contrast to their amino
acid counterparts, the respective
-keto acids corresponding to
isoleucine, leucine, and valine did not influence the uptake of BAY
10-8888 (data not shown). The D enantiomers of the
proteinaceous amino acids isoleucine, leucine, and valine were also
able to reduce the initial level of BAY 10-8888 uptake to 62, 66, and
79% of the control value, respectively, when the cells were
preincubated with a 100-fold excess of the respective amino acid for 3 min (data not shown).

View larger version (78K):
[in this window]
[in a new window]
|
FIG. 2.
Inhibition of BAY 10-8888 uptake by L-amino
acids (A) and effect of growth medium composition on BAY 10-8888 uptake
(B). (A) C. albicans BSMY 212 cells grown in YNG medium were
incubated with 50 µM [14C]BAY 10-8888 for 5 min in the
presence of 1 mM the respective L-amino acid (tyrosine at
0.5 mM). Cells were processed as described in Materials and Methods.
(B) C. albicans BSMY 212 cells were grown in different media
at 37°C (YNG, YNG medium; YNGW, YNG medium without amino acids; 5%
BSA, YNGWA medium containing 5% BSA as the nitrogen source; 30% serum
[30% S.], YNGWA medium containing 30% fetal calf serum as the
nitrogen source; 1 mM Ile, YNGWA medium containing 1 mM
L-Ile as the nitrogen source; 1 mM Asn, YNGWA medium
containing 1 mM L-Asn as the nitrogen source; YPG, YPG
medium). Cells were harvested by centrifugation and were resuspended in
growth medium, growth medium lacking the respective amino acid (cells
grown in the presence of isoleucine or asparagine), or PBS (YNG/PBS).
Thereafter, the cells were incubated with 50 µM
[14C]BAY 10-8888 for 30 min and were processed as
described in Materials and Methods. Relative transport rates are
indicated. The error bars indicate standard deviations.
|
|
Effect of growth medium.
Figure 2B shows that the relative
transport activity for BAY 10-8888 was also dependent on the source of
the growth medium nitrogen. Relative transport activity was identical
for cells grown in yeast nitrogen base-based media with ammonium
sulfate (YNGW), ammonium sulfate and amino acids (YNG), 5% BSA, 30%
fetal calf serum (30% serum), 1 mM isoleucine, or 1 mM asparagine as sources of nitrogen. Growth in medium containing peptone and yeast extract repressed BAY 10-8888 transport activity. Lack of energy sources during uptake of BAY 10-8888 (Fig. 2B, YNG/ PBS) reduced uptake
by about 50%.
Active uptake of BAY 10-8888 in C. albicans.
To measure
intracellular BAY 10-8888 concentrations, we determined the
intracellular volume (water space) of C. albicans BSMY 212 by the double-labelling method described in Materials and Methods. The
intracellular volume of 108 cells was 5.7 ± 1.8 µl
(n = 13) for cells grown in YNG medium and 3.8 ± 1.0 µl (n = 14) for 108 cells grown YPG
medium at 37°C. The morphological distribution of the populations was
determined by light microscopy. For C. albicans BSMY 212 grown in YPG medium, 85% single cells and 15% pseudohyphae were
observed. Cells grown in YNG medium were 50% single cells and 50%
pseudohyphae.
As shown in Fig.
3A
C. albicans cells grown in YNG medium at 37°C accumulated
[
14C]BAY 10-8888, which was added at a concentration of
50 µM (corresponding
to 7.1 µg of BAY 10-8888 per ml, which is
about twice the IC
90),
within 10 min up to an intracellular
concentration of about 5
mM. This concentration was maintained for at
least 50 min. In
contrast, an intracellular concentration of 0.4 mM was
measured
after 30 min for cells grown in YPG medium. Uptake was
identical
in PBS instead of YPG medium (data not shown). Thus, the
reduced
uptake in YPG medium was not due to the compounds in the medium
competing with BAY 10-8888 for uptake.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 3.
Uptake of BAY 10-8888. (A) C. albicans BSMY
212 cells grown in YNG or YPG medium at 37°C were incubated with 50 µM [14C]BAY 10-8888 in the same medium and were
processed as described in Materials and Methods. The mean ± standard deviation intracellular concentration (BAY
10-8888in) is presented. (B) Uptake of
[14C]BAY 10-8888 (1 µM to 8 mM) was measured at 37°C
over a period of 3 min. Data represent means ± standard
deviations. The dashed line represents a nonlinear fit. (Inset)
Respective Hanes plot. (C) Dependence of intracellular (BAY
10-8888in) and medium (BAY 10-8888med)
concentration on cell density. C. albicans BSMY 212 cells
grown in YNG medium were incubated with 50 µM [14C]BAY
10-8888 for 30 min in the same medium at different cell densities.
Thereafter, the cells were processed as described in Materials and
Methods. Mean ± standard deviation intracellular and medium
concentrations are shown. The dashed lines represent a nonlinear fit.
|
|
The dependency of BAY 10-8888 uptake on the concentration in the medium
(BAY 10-8888
med) during a 3-min incubation can be
described
by a Michaelis-Menten equation (Fig.
3B). Uptake was
saturable with a
KT (Michaelis constant of the transport
reaction)
of 0.95 mM and a
Vmax of 18.9 nmol × min
1 × 10
7
cells
1. Assuming a dry weight similar to that of diploid
S. cerevisiae (20 pg/cell [
23]), this
corresponds to 94.5 nmol/min per mg
of cell (dry weight).
We used a cell density of 10
8/ml for our transport studies.
At this cell density the medium concentration of BAY 10-8888 decreased
from an initial concentration of 50 µM to one of 21 µM after 30
min
(Fig.
3C). The decrease in the cell density resulted in an
increase in
the intracellular BAY 10-8888 concentration up to
14 mM at a cell
density of 10
6 cells/ml (Fig.
3C), while the concentration
in the medium remained
essentially unchanged (50 µM). Overall,
C. albicans BSMY 212 cells
grown in YNG medium accumulated
BAY 10-8888 to a concentration
about 200 that in the medium.
Characterization of active transport.
The influence of several
metabolic inhibitors and ionophores on BAY 10-8888 uptake is shown in
Table 2. The proton ionophores carbonylcyanide-m-chlorophenylhydrazone (CCCP) and
carbonylcyanide p-trifluoromethoxyphenylhydrazone reduced
uptake to 7 and 25% of the control value when the cells were
preincubated with 100 µM ionophore for 5 and 1 min, respectively.
This suggested that uptake of BAY 10-8888 is proton linked. Metabolic
inhibitors such as sodium cyanide and sodium azide reduced transport
activity to 40 and 10% of the control value, respectively. The
ionophores valinomycin and nigericin reduced the uptake of BAY 10-8888 to about 40% of the control value. N-Ethylmaleimide, which
covalently modifies cysteine side chains, reduced uptake to 1.6% of
the control value. As expected, the addition of SDS completely
abolished BAY 10-8888 accumulation. The initial velocity of BAY 10-8888 uptake was measured at different pH values. The uptake showed a maximum at pH 6.0 and decreased to 6 and 8% of the control value at pH 4.0 and
pH 9.0, respectively (data not shown).
Efflux studies.
Efflux was studied after the preloading of
C. albicans cells with BAY 10-8888. The cells were incubated
in YNG medium containing 50 µM BAY 10-8888 for 30 min. Thereafter,
the cells were washed and resuspended in fresh YNG medium or YNG medium
containing 1 mM L-isoleucine, and the intracellular BAY
10-8888 concentration was monitored (Fig.
4A). Initially, the intracellular
concentration of BAY 10-8888 was 7.1 mM and it declined exponentially
to 2.7 mM within 1 h. Thereafter, a slower decrease to 1.5 mM
after an additional 17 h was observed. In cells, preloaded in PBS
instead of YNG medium, the initial intracellular concentration of BAY 10-8888 was 4.15 mM, which decreased to 0.34 mM after 18 h. The addition of 1 mM L-isoleucine to the medium did not
influence BAY 10-8888 efflux. In contrast to amino acid transporters
from bacteria and mammalian cells, internalized amino acids do not efflux after deenergization of yeast cells (7, 8, 13). To
test this hypothesis for BAY 10-8888, the influences of detergent, metabolic inhibitors in combination with proton ionophore and sulfhydryl-modifying agents on BAY 10-8888 efflux were tested over a
period of 30 min (Fig. 4B), and the influence on efflux was compared to
that on influx (Table 2). As expected, the addition of detergent (0.1%
SDS) reduced the level of BAY 10-8888 uptake to below 15% of the
untreated control value and resulted in the release of BAY 10-8888 from
preloaded cells within 10 min. The addition of 30 mM sodium azide in
combination with 0.1 mM CCCP reduced the level of uptake to 8% of the
control value after 30 min, while the same treatment was not efficient
in increasing the level of efflux of BAY 10-8888 from preloaded
C. albicans cells. The cells retained 79% of the
radioactivity retained by the untreated control. Furthermore, the
larger amount of retained BAY 10-8888 in untreated cells may reflect
reuptake of BAY 10-8888 instead of reduced efflux. This suggested that
uptake of BAY 10-8888 is unidirectional or, at least, that the
transport into the cell is strongly favored and efflux occurred in a
carrier-independent manner. Treatment of C. albicans with 10 mM N-ethylmaleimide reduced uptake to below 9% of the
control value by modification of the sulfhydryl groups of the
transporter as well as other proteins (Table 2). The addition of 10 mM
N-ethylmaleimide to cells which already received 30 mM
sodium azide and 0.1 mM CCCP did not influence efflux (Fig. 4B).

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 4.
Time course of BAY 10-8888 efflux. (A) Logarithmic-phase
C. albicans cells grown at 37°C in YNG medium were
preloaded with 50 µM [14C]BAY 10-8888 for 30 min. Cells
preloaded in YNG medium were pelleted by centrifugation, washed once,
and resuspended in YNG medium or YNG medium containing 1 mM isoleucine.
Cells preloaded in PBS were resuspended in PBS or PBS containing 1 mM
isoleucine. At the indicated time points, the intracellular
concentration of BAY 10-8888 was determined. (B) Logarithmic-phase
C. albicans cells grown at 37°C in YNG medium were
preloaded with 50 µM [14C]BAY 10-8888 for 30 min. The
cells were pelleted by centrifugation, washed once, and resuspended in
YNG medium or YNG medium containing 0.1% SDS, 30 mM sodium azide, and
0.1 mM CCCP or 30 mM sodium azide, 0.1 mM CCCP, and 10 mM
N-ethylmaleimide (NEM). At the indicated time points, the
intracellular radioactivity was determined. The error bars indicate
standard deviations. The dashed lines represent a nonlinear fit.
|
|
Reversion of BAY 10-8888-induced growth inhibition inside the cell
by L-isoleucine.
As shown above, at 1 mM
L-isoleucine the antifungal activity of BAY 10-8888 was
reduced at least eightfold compared to the level of reduction obtained
with any other amino acid tested. We therefore investigated whether
L-isoleucine not only competed for uptake but was also able
to reverse BAY 10-8888-induced growth inhibition by an intracellular
mechanism. C. albicans cells from an overnight culture in
YNG medium at 37°C were inoculated at a cell density of about
106 cell/ml in YNG medium and were equilibrated to 37°C
for 2 h. Thereafter, either [14C]BAY 10-8888 (final
concentration, 50 µM, 0.05 µCi/ml) or [14C]BAY
10-8888 (50 µM, 0.05 µCi/ml) and L-isoleucine (1 mM),
L-isoleucine (1 mM), or PBS (no addition) were added, and
growth was assessed by determining the numbers of CFU after 0, 1.5, 3, and 6 h (Fig. 5A). After a lag phase
of about 3 h, the CFU count increased about 10-fold during the
next 3 h in the control sample and the samples containing 1 mM
L-isoleucine and 50 µM BAY 10-8888 or 1 mM
L-isoleucine. In contrast, no growth was observed in the
culture containing 50 µM BAY 10-8888 only. The intracellular
concentrations of BAY 10-8888 were about 10 and 6.5 mM 1 and 2 h,
respectively, after the addition of either 50 µM BAY 10-8888 only or
50 µM BAY 10-8888 and 1 mM L-isoleucine (Fig. 5B). Thus,
the presence of a 20-fold excess of L-isoleucine did not
influence the accumulation of BAY 10-8888 under equilibrium conditions.
In cells incubated with BAY 10-8888 at a concentration of 50 µM the
intracellular concentration decreased to 5.2 mM after 4 h and
increased again to 9.5 mM after 6 h. In cells incubated with 50 µM BAY 10-8888 and 1 mM L-isoleucine the intracellular
concentrations decreased to 2.2 and 3.7 mM after 4 and 6 h,
respectively. The calculations of the values at 4 and 6 h were
performed by taking into account the increase in the total cell volume
during growth after 4 and 6 h. Growth was recorded by determining
the numbers of CFU. The increase in the numbers of CFU may be higher
than the increase in cell volume, and therefore, our calculated values
may underestimate the BAY 10-8888 concentrations inside the cells.
Overall, the intracellular BAY 10-8888 concentration was the same in
the presence and absence of additional isoleucine in the medium. We
also observed an absolute increase in the amount of radioactivity
retained inside the cells at these time points (data not shown). It is
evident from Fig. 5 that intracellular BAY 10-8888 at millimolar
concentrations inhibits the growth of C. albicans and,
furthermore, that this growth inhibition can be reversed by
L-isoleucine.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 5.
L-Isoleucine reversion of BAY
10-8888-induced growth inhibition inside the cell. C. albicans BSMY 212 cells from an overnight culture in YNG medium at
37°C were equilibrated at a cell density of about 106
cell/ml in YNG medium to 37°C for 2 h. Thereafter, either
[14C]BAY 10-8888 (final concentration, 50 µM;
radioactivity concentration, 0.05 µCi/ml) or [14C]BAY
10-8888 (50 µM; 0.05 µCi/ml) and L-isoleucine (1 mM),
L-isoleucine (1 mM), or PBS (no addition) were added and
growth was recorded (A). In samples that received BAY 10-8888, the
intracellular concentration was determined as described in Materials
and Methods (B).
|
|
BAY 10-8888-induced inhibition of protein biosynthesis.
The
reversion of BAY 10-8888-induced growth inhibition by
L-isoleucine suggests that the intracellular target of BAY
10-8888 is part of the L-isoleucine metabolism.
Endogenously synthesized L-isoleucine is charged with tRNA
and is incorporated into proteins, while the carbon skeleton of
externally acquired L-isoleucine can also be fed into the
citric acid cycle after transamination to
DL-
-keto-
-methylvaleric acid. Since
DL-
-keto-
-methylvaleric acid was far less efficient
than L-isoleucine in overcoming BAY 10-8888-induced growth
inhibition (Table 1), a target within L-isoleucine
biosynthesis or metabolism seemed less likely. We therefore
investigated the influence of BAY 10-8888 on protein and nucleic acid
biosynthesis as well as tRNA charging.
The addition of 8 µg of BAY 10-8888 per ml (56 µM) to a
C. albicans cell suspension reduced the level of
[
14C]lysine incorporation to below 10% of the control
value within
20 min and remained constantly low over the time period
(90 min)
investigated, while the concomitant addition of 1 mM
L-isoleucine
prevented BAY 10-8888-induced protein
synthesis inhibition (Fig.
6A). No
significant difference in the level of [
14C]adenine
incorporation between cells incubated in the absence
or presence of 56 µM BAY 10-8888 or 56 µM BAY 10-8888 and 1 mM
L-isoleucine could be detected (data not shown). This
suggested
that protein biosynthesis rather than nucleic acid metabolism
was affected by BAY 10-8888.

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 6.
Inhibition of protein biosynthesis and incorporation of
BAY 10-8888 into proteins. (A) Logarithmic-phase C. albicans
BSMY 212 cells grown in YNG medium at 37°C were incubated at a cell
density of 107/ml in YNG medium (no addition), YNG medium
containing 56 µM BAY 10-8888, or YNG medium containing 56 µM BAY
10-8888 and 1 mM L-isoleucine. After the indicated time
points, a sample was taken and the level of [14C]lysine
incorporation into TCA-precipitable material was measured for 10 min as
described in Materials and Methods. The relative level of incorporation
(the value at time zero minutes corresponds to 100%) is shown. (B)
Duplicate samples of logarithmic-phase C. albicans BSMY 212 cells grown in YNG medium at 37°C were incubated at a cell density of
108/ml in YNG medium containing 50 µM
[14C]BAY 10-8888 or 50 µM
L-[14C]lysine for 30 min at 37°C.
Thereafter, the intracellular concentrations of the respective amino
acid and TCA-precipitable radioactivity were determined as described in
Materials and Methods. The error bars indicate standard deviations.
|
|
To test whether BAY 10-8888 is charged to tRNA and is incorporated into
protein, duplicate samples of
C. albicans BSMY 212
were
incubated with 50 µM [
14C]BAY 10-8888 or 50 µM
L-[
14C]lysine for 30 min at 37°C.
Thereafter, the intracellular amount
of radioactivity, which could be
precipitated by TCA and which
was therefore attributable to either
charged tRNA or to incorporation
into protein, was determined (Fig.
6B). Within 30 min the intracellular
amount of
L-lysine
increased to 8 mM, including the fraction incorporated
into
macromolecules. Approximately 50% of the accumulated
L-lysine
was incorporated into protein or was charged to
tRNA. BAY 10-8888
was accumulated to an intracellular concentration of
6.3 mM; however,
only as little as 2% of this amount could be
precipitated by TCA.
This indicated that little, if any, BAY 10-8888 was charged to
tRNA and incorporated into proteins.
Inhibition of C. albicans isoleucyl-tRNA synthetase by
BAY 10-8888.
We determined the specific activity of isoleucyl-tRNA
synthetase in the S100 extract from C. albicans cells grown
in YNG or YPG medium at 37°C using tRNA from brewer's yeast as the
substrate. The specific activities for isoleucyl-tRNA synthetase were
0.11 and 0.17 U/mg of protein for cells grown in YNG and YPG medium, respectively. These specific activities were of the same order of
magnitude as those reported for crude extracts of S. cerevisiae (27). Isoleucyl-tRNA synthetase activity was
inhibited by BAY 10-8888 at increasing concentrations (Fig.
7A). No difference was observed between
cells grown in YNG medium and cells grown in YPG medium. In contrast,
lysyl-tRNA synthetase activity, a different aminoacyl-tRNA synthetase,
was not inhibited in the presence of BAY 10-8888 (data not shown).
Using S100 extracts from cells grown in YNG medium as the source of
isoleucyl-tRNA activity, we determined a Ki
value for BAY 10-8888 by measuring synthetase activity in the presence
of 0, 1, and 5 mM BAY 10-8888 with increasing isoleucine concentrations
(1-20 µM). The Ki was calculated to be 1 mM
(data not shown). As shown above, C. albicans BSMY 212 cells
grown in YNG medium at a cell density of about 107/ml
accumulated BAY 10-8888 about 200-fold within 30 min. We compared the
concentration-dependent relative inhibition of isoleucyl-tRNA synthetase activity and protein biosynthesis taking into account a
200-fold accumulation of BAY 10-8888. As shown in Fig. 7B, inhibition of isoleucyl-tRNA synthetase activity and protein biosynthesis had
identical dependencies on the BAY 10-8888 concentration. This suggested
that BAY 10-8888-induced inhibition of isoleucyl-tRNA synthetase
results in the inhibition of protein synthesis.

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 7.
Correlation of inhibition of isoleucyl-tRNA synthetase
activity with inhibition of protein synthesis. (A) Isoleucyl-tRNA
synthetase activity was determined in an S100 extract from C. albicans cells grown in YNG or YPG medium at 37°C. (B) The
concentration-dependent relative inhibition of isoleucyl-tRNA
synthetase and protein biosynthesis activity were compared.
Isoleucyl-tRNA synthetase activity was determined in an S100 extract
from C. albicans cells grown in YNG medium at 37°C. The
relative activity of protein biosynthesis was determined by incubation
of logarithmic-phase C. albicans BSMY 212 cells grown in YNG
medium at 37°C for 20 min at a cell density of 107/ml,
with BAY 10-8888 used at a concentration 200-fold less than shown on
the x axis. As indicated in Results, cells accumulate BAY
10-8888 about 200-fold under these conditions. Thereafter, the level of
incorporation of [14C]lysine was determined as described
in Materials and Methods. The dashed lines represent nonlinear fits
assuming a Gaussian distribution. The error bars indicate standard
deviations.
|
|
Decrease of BAY 10-8888 sensitivity by overexpression of
isoleucyl-tRNA synthetase in S. cerevisiae.
Initial attempts
to express S. cerevisiae isoleucyl-tRNA synthetase in
C. albicans under the control of the actin promoter failed.
This was most likely due to the unusual codon usage in C. albicans that prohibits expression of many S. cerevisiae genes in C. albicans (16, 24). We
therefore tested the effect of overexpression of isoleucyl-tRNA
synthetase on BAY 10-8888 sensitivity in S. cerevisiae. We
cloned the coding region of S. cerevisiae isoleucyl-tRNA
synthetase into plasmid pG-1, which allows constitutive expression of
the synthetase under the control of the strong
glyceraldehyde-3-phosphate dehydrogenase promoter. The resulting
construct (pAL664) was introduced into S. cerevisiae ATCC
46790. Lysates prepared from cells grown under selective conditions
were assayed for isoleucyl- and lysyl-tRNA synthetase activities.
Compared to control transformants (pG-1), the specific activity of
isoleucyl-tRNA synthetase was increased sevenfold in cells grown in YNG
medium and eightfold in cells grown in minimal dextrose medium for
transformants harboring plasmid pAL664 (Table
3). The activity of an unrelated
aminoacyl-tRNA synthetase, lysyl-tRNA synthetase, remained unchanged.
Sensitivity to BAY 10-8888 decreased two- and fourfold for cells
overexpressing isoleucyl-tRNA synthetase grown in YNG medium and
minimal dextrose medium, respectively. In contrast, the
IC90 of fluconazole, an azole antifungal agent, was 16 µg/ml for both transformants.
View this table:
[in this window]
[in a new window]
|
TABLE 3.
Decreased susceptibility of S. cerevisiae to
BAY 10-8888 by overexpression of isoleucyl-tRNA
synthetasea
|
|
 |
DISCUSSION |
We investigated the mode of action of BAY 10-8888, a cyclic
-amino acid with antifungal activity in C. albicans. Our
data showed that BAY 10-8888 has a dual mode of action, namely,
inhibition of isoleucyl-tRNA synthetase after concentrative uptake.
BAY 10-8888 serves as an artificial substrate and is accumulated by an
H+-coupled symporter specific for branched-chain amino
acids. In contrast, L-proline did not compete for BAY
10-8888 uptake, as has been shown for cispentacin (2, 10).
This suggests that different
-amino acids use different carrier
systems. With an apparent KT of 0.96 mM, BAY
10-8888 is a low-affinity substrate for its carrier. C. albicans has a high capacity for BAY 10-8888 transport, with
uptake being 94.5 nmol/min per mg of cell (dry weight) at 37°C. This
value is higher than those reported for the uptake of any other
naturally occurring amino acid in S. cerevisiae (7). Accumulation of BAY 10-8888 is observed if cells are
grown in a variety of nitrogen sources including ammonium ions, amino acids, protein, and serum. In addition, preliminary data indicate that
BAY 10-8888 is also accumulated in C. albicans cells
isolated from the kidneys of infected mice (data not shown). This
strongly suggests that the BAY 10-8888 carrier is expressed during
infection. The accumulation factor (200-fold) that we observed for BAY
10-8888 in C. albicans is of the same order of magnitude as
the accumulation factor determined for the naturally occurring amino
acid glycine in S. cerevisiae (7). At the lower
cell densities (103/ml) used for susceptibility testing,
the accumulation factor may be even higher. The high intracellular
concentration necessary for growth inhibition suggests that BAY 10-8888 either interferes nonspecifically with cellular metabolism, as proposed
for cispentacin (2), or has a low affinity for its
intracellular target. Our data support the latter conclusion (see
below). Carrier activity in medium (YPG) containing peptone and yeast
extract as nitrogen sources is low and correlates with the low level of
BAY 10-8888 accumulation and high IC90. This indicates that
active accumulation is a prerequisite for the in vitro antifungal
activity of BAY 10-8888, since at the same time no difference in the
level of inhibition of the intracellular target isoleucyl-tRNA
synthetase was observed between YPG medium and YNG medium.
In C. albicans about 10 amino acid transporters have been
characterized by their different substrate specificities (4, 20). Nitrogen catabolite repression seems to be absent from C. albicans (28). Recently, a transporter for
basic amino acids was cloned from C. albicans in
complementation experiments with an S. cerevisiae mutant
(25). This carrier showed a high degree of homology to both
transporters for basic amino acids (Can1 and Lyp1) from S. cerevisiae (26), suggesting a high degree of
conservation at the molecular level between these two species. The gene
which encodes the transporter for BAY 10-8888 awaits further
characterization.
In yeast, the accumulation of amino acids from the external medium into
the cell occurs by unidirectional flux (7, 8, 13). This
unidirectional flux is not related to the trapping of amino acids in
the vacuole (19). We have shown that BAY 10-8888 is
accumulated unidirectionally and leaves the cells only by diffusion, as
is the case for proline in S. cerevisiae (8). Our
evidence is based on the different effects of metabolic inhibitors in
combination with protein ionophores and sulfhydryl blockers. While
influx of BAY 10-8888 is strongly inhibited by these compounds, they have no effect on efflux. This may be important for the antifungal activity of BAY 10-8888, because deenergization as a result of the
action of BAY 10-8888 does not lead to the immediate release of the
highly accumulated compound through the uncoupled transporter and,
subsequently, a decrease in its antifungal activity. Furthermore, efflux is independent from the presence of an excess of isoleucine in
the medium. This indicates that the influx of isoleucine does not
interfere with BAY 10-8888 efflux; i.e., changes in tissue or serum
isoleucine levels will not interfere with the in vivo antifungal
activity of BAY 10-8888.
Inside the cell, competitive inhibition of isoleucyl-tRNA synthetase is
responsible for the antifungal activity of BAY 10-8888. Our conclusion
is based on multiple lines of evidence. First, L-isoleucine
is able to reverse BAY 10-8888-induced growth inhibition not only by
competing with uptake but also by competing at the intracellular
target. The compensatory effects of L-leucine and L-valine on growth inhibition by BAY 10-8888 are small
compared to the effects of L-isoleucine. This can be
explained either by competition at the carrier level or by an indirect
influence on the intracellular L-isoleucine concentration.
The effects of the D-amino acids may result from
competition at the carrier level, because these amino acids are not
incorporated into proteins. Second, BAY 10-8888 inhibits isoleucyl-tRNA
synthetase from C. albicans competitively in a
concentration-dependent manner. The Ki of about
1 mM, which is unusually high for an enzyme inhibitor, suggests that
the interaction of isoleucyl-tRNA synthetase with BAY 10-8888 is not
very specific. Nevertheless, overexpression of endogenous
isoleucyl-tRNA synthetase in S. cerevisiae resulted in a
small (two- to fourfold) but reproducible decrease in sensitivity to
BAY 10-8888. The decrease in the sensitivity to BAY 10-8888 was
comparable to the decrease in the sensitivity to azoles for a S. cerevisiae transformant overexpressing cytochrome P-450-dependent lanosterol 14-
-demethylase, the target of azole antifungal agents (11). In addition, a different aminoacyl-tRNA synthetase,
lysyl-tRNA synthetase, is not inhibited by BAY 10-8888. Taking into
account a 200-fold accumulation of BAY 10-8888, protein biosynthesis in intact C. albicans cells and isoleucyl-tRNA synthetase were
inhibited by the same concentrations of BAY 10-8888. This suggests that charging of tRNA is a rate-limiting step in protein biosynthesis. An
S. cerevisiae mutant showing temperature-sensitive protein biosynthesis was found to have a thermolabile isoleucyl-tRNA synthetase (6). This provides additional evidence that protein
biosynthesis in yeasts is very sensitive to the loss or inhibition of
isoleucyl-tRNA synthetase activity.
Inhibition of protein biosynthesis is the mode of action of several
antibacterial agents successfully used in clinical practice (15). BAY 10-8888 is among the first of the antifungal drugs that block protein biosynthesis. The unique mode of action which differs from those of other antifungal compounds presently available or
under development makes BAY 10-8888 a promising candidate for further
clinical development.
 |
ACKNOWLEDGMENTS |
We gratefully acknowledge G. Munack, MPI für Experimentelle
Medizin, Göttingen, Germany, for providing the S. cerevisiae isoleucyl-tRNA synthetase gene. We thank S. Badock and
A. Ludwig for excellent technical assistance.
 |
FOOTNOTES |
*
Corresponding author. Present mailing address: Bayer
Yakuhin Ltd., Research Center Kyoto, 6-5-1-3 Kunimidai, Kizu-cho,
Soraku-gun, Kyoto, 619-02, Japan. Phone: (81)774 75-2462. Fax: (81)774
75-2507. E-mail: karl.ziegelbauer.kz{at}bayer-ag.de.
 |
REFERENCES |
| 1.
| Babczinski, P. Unpublished results.
|
| 1a.
| Bremm, K., R. Endermann, F. Kunisch, M. Matzke,
K.-G. Metzger, H. Militzer, J. Mittendorf, and M. Plempel. May 1993. EP patent 571,870.
|
| 2.
|
Capobianco, J.,
D. Z. Zakula,
M. L. Coen, and R. C. Goldman.
1993.
Anti-Candida activity of cispentacin: the active transport by amino acid permeases and possible mechanisms of action.
Biochem. Biophys. Res. Commun.
190:1037-1044[Medline].
|
| 3.
|
Fasoli, M. O. F., and D. Kerridge.
1990.
Uptake of pyrimidines and their derivatives into Candida glabrata and Candida albicans.
J. Gen. Microbiol.
136:1475-1481[Abstract/Free Full Text].
|
| 3a.
| Geschke, F. U., A. Schmidt, and W. Schönfeld. Unpublished results.
|
| 4.
|
Gupta, P.,
S. K. Mahanty,
S. Ansari, and R. Prasad.
1992.
Transport of acidic amino acids in Candida albicans.
J. Met. Vet. Mycol.
30:27-34.
|
| 5.
|
Hampel, A. E.,
M. D. Enger, and P. O. Ritter.
1979.
Aminoacyl-tRNA synthetases from cultured CHO cells.
Methods Enzymol.
59:229-234[Medline].
|
| 6.
|
Hartwell, L. H., and C. S. McLaughlin.
1968.
Mutants of yeast with temperature-sensitive isoleucyl-tRNA synthetases.
Proc. Natl. Acad. Sci. USA
59:422-428[Free Full Text].
|
| 7.
|
Horak, J.
1986.
Amino acid transport in eucaryotic microorganisms.
Biochim. Biophys. Acta
864:223-256[Medline].
|
| 8.
|
Horak, J., and L. Rihova.
1982.
L-Proline transport in Saccharomyces cerevisiae.
Biochim. Biophys. Acta
691:144-150[Medline].
|
| 9.
|
Iwamoto, T.,
E. Tsujii,
M. Ezaki,
A. Fujie,
S. Hashimoto,
M. Okuhara,
M. Kohsaka, and H. Imanaka.
1990.
FR109615, a new antifungal antibiotic from Streptomyces setonii: taxonomy, fermentation, isolation, physico-chemical properties and biological activity.
J. Antibiot.
43:1-7[Medline].
|
| 10.
|
Jethwaney, D.,
M. Hofer,
R. K. Khaware, and R. Prasad.
1997.
Functional reconstitution of a purified proline permease from Candida albicans: interaction with the antifungal cispentacin.
Microbiology
143:397-404[Abstract/Free Full Text].
|
| 11.
|
Kirsch, D. R.,
M. H. Lai, and J. O. O'Sullivan.
1988.
Isolation of the gene for cytochrome P450L1A1 (lanosterol 14 alpha-demethylase) from Candida albicans.
Gene
68:229-237[Medline].
|
| 12.
|
Konishi, M.,
M. Nishio,
K. Saitoh,
T. Miyaki,
T. Oki, and K. Kawaguchi.
1989.
Cispentacin, a new antifungal antibiotic. I. Production, isolation, physico-chemical properties and structure.
J. Antibiot.
42:1749-1755[Medline].
|
| 13.
|
Kotyk, A., and L. Rihova.
1972.
Transport of -aminoisobutyric acid in Saccharomyces cerevisiae.
Biochim. Biophys. Acta
288:380-389[Medline].
|
| 14.
|
Munack, G.
1994.
Ph.D. thesis.
University of Braunschweig, Braunschweig, Germany.
|
| 15.
|
Murray, P. R.,
G. S. Kobayashi,
M. A. Pfaller, and K. S. Rosenthal.
1994.
Medical microbiology.
Mosby-Year Book, Inc., London, United Kingdom.
|
| 16.
|
Ohama, T.,
T. Suzuki,
M. Mori,
S. Osawa,
T. Ueda,
K. Watanabe, and T. Nakase.
1993.
Non-universal decoding of the leucine codon CUG in several Candida species.
Nucleic Acids Res.
21:4039-4045[Abstract/Free Full Text].
|
| 17.
|
Ohki, H.,
Y. Inamoto,
K. Kawabata,
T. Kamimura, and K. Sakane.
1991.
Synthesis and antifungal activity of FR109615 analogs.
J. Antibiot.
44:546-549[Medline].
|
| 18.
|
Oki, T.,
M. Hirano,
K. Tomatsu,
K. Numata, and H. Kamei.
1989.
Cispentacin, a new antifungal antibiotic. II. In vitro and in vivo antifungal activities.
J. Antibiot.
42:1756-1762[Medline].
|
| 19.
|
Opekarova, M.,
T. Caspari, and W. Tanner.
1993.
Unidirectional arginine transport in reconstituted plasma-membrane vesicles from yeast overexpressing CAN1.
Eur. J. Biochem.
211:683-688[Medline].
|
| 20.
|
Prasad, R.
1987.
Nutrient transport in Candida albicans, a pathogenic yeast.
Yeast
3:209-221[Medline].
|
| 21.
|
Rottenberg, H.
1979.
The measurement of membrane potential and delta pH in cells, organelles, and vesicles.
Methods Enzymol.
55:547-569[Medline].
|
| 22.
|
Schena, M.,
D. Picard, and K. Yamamoto.
1991.
Vectors for constitutive and inducible gene expression in yeast.
Methods Enzymol.
194:389-398[Medline].
|
| 23.
|
Sherman, F.
1991.
Getting started with yeast.
Methods Enzymol.
194:3-21[Medline].
|
| 24.
|
Sumiyama, H.,
M. Ohkuma,
Y. Masuda,
S.-M. Park,
A. Ohta, and M. Takagi.
1995.
In vivo evidence for non-universal usage of the codon CUG in Candida maltosa.
Yeast
11:43-52[Medline].
|
| 25.
|
Sychrova, H., and M.-R. Chevallier.
1993.
Transport properties of a C. albicans amino-acid permease whose putative gene was cloned and expressed in S. cerevisiae.
Curr. Genet.
24:487-490[Medline].
|
| 26.
|
Sychrova, H., and J.-L. Souciet.
1994.
CAN1, a gene encoding a permease for basic amino acids in Candida albicans.
Yeast
10:1647-1651[Medline].
|
| 27.
|
Van der Haar, F.
1979.
Purification of aminoacyl-tRNA synthetases.
Methods Enzymol.
59:257-267[Medline].
|
| 28.
|
Verma, R. S., and R. Prasad.
1983.
Absence of derepression of amino acids transport in Candida.
Biochem. Int.
7:707-717[Medline].
|
Antimicrobial Agents and Chemotherapy, September 1998, p. 2197-2205, Vol. 42, No. 9
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Hasenoehrl, A., Galic, T., Ergovic, G., Marsic, N., Skerlev, M., Mittendorf, J., Geschke, U., Schmidt, A., Schoenfeld, W.
(2006). In Vitro Activity and In Vivo Efficacy of Icofungipen (PLD-118), a Novel Oral Antifungal Agent, against the Pathogenic Yeast Candida albicans.. Antimicrob. Agents Chemother.
50: 3011-3018
[Abstract]
[Full Text]
-
Hurdle, J. G., O'Neill, A. J., Chopra, I.
(2005). Prospects for Aminoacyl-tRNA Synthetase Inhibitors as New Antimicrobial Agents. Antimicrob. Agents Chemother.
49: 4821-4833
[Full Text]
-
Petraitiene, R., Petraitis, V., Kelaher, A. M., Sarafandi, A. A., Mickiene, D., Groll, A. H., Sein, T., Bacher, J., Walsh, T. J.
(2005). Efficacy, Plasma Pharmacokinetics, and Safety of Icofungipen, an Inhibitor of Candida Isoleucyl-tRNA Synthetase, in Treatment of Experimental Disseminated Candidiasis in Persistently Neutropenic Rabbits. Antimicrob. Agents Chemother.
49: 2084-2092
[Abstract]
[Full Text]
-
Petraitis, V., Petraitiene, R., Kelaher, A. M., Sarafandi, A. A., Sein, T., Mickiene, D., Bacher, J., Groll, A. H., Walsh, T. J.
(2004). Efficacy of PLD-118, a Novel Inhibitor of Candida Isoleucyl-tRNA Synthetase, against Experimental Oropharyngeal and Esophageal Candidiasis Caused by Fluconazole-Resistant C. albicans. Antimicrob. Agents Chemother.
48: 3959-3967
[Abstract]
[Full Text]
-
Zgodka, D., Milewski, S., Borowski, E.
(2001). A diffusible analogue of N3-(4-methoxyfumaroyl)-L-2,3-diaminopropanoic acid with antifungal activity. Microbiology
147: 1955-1959
[Abstract]
[Full Text]
-
Grosshans, H., Hurt, E., Simos, G.
(2000). An aminoacylation-dependent nuclear tRNA export pathway in yeast. Genes Dev.
14: 830-840
[Abstract]
[Full Text]
-
Andriole, V. T.
(1999). Current and future antifungal therapy: new targets for antifungal agents. J Antimicrob Chemother
44: 151-162
[Abstract]
[Full Text]